Most incretin-based therapies drive impressive fat loss, but at a cost: significant lean mass depletion worse metabolic health higher long-term risk, especially in Diabetes This graphic highlights a two-pronged approach: Semaglutide reduces appetite & fat mass Bimagrumab blocks ActRIIA/B signalling, preventing muscle atrophy Clinical data (BELIEVE trial) shows that combining the two: enhances fat loss preserves or increases lean mass improves overall body composition, not just the number on the scale In a season where weight gain is almost guaranteed, the future of obesity treatment isnt eat less and lose everything. Its lose fat while building muscle
Gentle swirling or rolling the vial between the palms achieves full dissolution without that risk, which is why its the standard technique across peptide research protocols rather than an arbitrary preference
If headaches persist beyond two weeks at your current dose, PlexusDx clinicians can evaluate whether dose timing adjustments or hydration protocols might help, rather than requiring a dose change
Pricing Transparency All-inclusive pricing is shown upfront and includes medication, supplies, medical consultations, and ongoing support
FDA adverse event data The FDA Adverse Event Reporting System (FAERS) database provides additional context